APA (7th ed.) Citation

Ivens, I. A., Achanzar, W., Baumann, A., Brändli-Baiocco, A., Cavagnaro, J., Dempster, M., . . . Sims, J. (2015). PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development. Toxicologic pathology, 43(7), 959. https://doi.org/10.1177/0192623315591171

Chicago Style (17th ed.) Citation

Ivens, Inge A., et al. "PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development." Toxicologic Pathology 43, no. 7 (2015): 959. https://doi.org/10.1177/0192623315591171.

MLA (9th ed.) Citation

Ivens, Inge A., et al. "PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development." Toxicologic Pathology, vol. 43, no. 7, 2015, p. 959, https://doi.org/10.1177/0192623315591171.